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Jenneke J. Deelstra, MD,*y Danielle Neut, PhD,*y and Paul C. Jutte, MD, PhD*Abstract:We present a rare case of an immunocompetent host who developed a Candida albicans–
infected total hip prosthesis. The infection could not be eradicated with debridement and extensive
antifungal therapy. Our patient first underwent a resection of the proximal femur and local
treatment with gentamicin-loaded cement beads. In a second procedure, a handmade cement
spacer impregnated with voriconazole, amphotericin B, and vancomycin was placed. After 3
months of additional systemic antibiotic therapy, the patient remained afebrile, and a tumor
prosthesis was placed. Six years postoperatively, she is doing well, walking with a small limp and
no signs of recurrent infection. This is the first report on elution of voriconazole and amphotericin
B from bone cement delivered at clinically significant concentrations for at least 72 hours.
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© 2013 Elsevier Inc.Open access under the Elsevier OA license.Periprosthetic joint infections are one of the most
dreaded and complex complications of total joint
arthroplasty [1]. Periprosthetic infections with fungi,
although rare, represent a therapeutic challenge for
which clear guidelines have not yet been established [2].
With few reported cases and the variety of treatment
regimens used, no single, deﬁnite protocol has emerged
for the treatment of these infections. Most experience to
treat fungal joint infections is with intravenous systemic
drug therapy [3]. Amphotericin B and ﬂuconazole are
regarded to be the drugs of choice for systemic
administration in patients who have Candida infections.
However, amphotericin B is one of the most toxic drugs;
side effects include immediate infusion-related reactions
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Open access under the Elsevier OA license.failure, anemia, hypokalemia, and occasional leucopenia
and thrombocytopenia [4]. Local antifungal administra-
tion can be used to achieve much higher concentration
(up to 1000-fold) than what systemic antifungals can
achieve, without the systemic side effects.
Most patients require removal of the components and
resection arthroplasty to cure a periprosthetic joint
infection [5]. A 2-stage revision for infected totally
replaced hip joints may involve a temporary spacer
impregnated with antibiotics allowing elution of antibi-
otics directly into the infected tissue bed, ﬁlling the dead
space, maintaining soft-tissue length, and allowing
limited walking before placing the new prosthesis [6].
The utility of antibiotic-impregnated cement spacers for
bacterial periprosthetic joint infections was ﬁrst reported
around the 1990s [7]. However, little is known about
cement depot delivery of antifungal agents for treatment
of periprosthetic infections, and literature shows a
problem regarding the impregnation of bone cement
with antifungal agents. In vitro studies of amphotericin
B– and ﬂuconazole impregnated cement have shown
poor elution characteristics for both agents [5,8].
Our case describes an immunocompetent patient with
Candida albicans–infected total hip prosthesis. The patient
was successfully treated with a segmental resection,
rigorous debridement, and a staged conversion using a5
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cement and impregnatedwith high contents of voricona-
zole, amphotericin B, and vancomycin. To our knowl-
edge, there are no previous case reports of antifungal-
impregnated cement spacers with proven clinical high
local concentrations of these agents for at least 72 hours.
Case Report
A 73-year-old woman was admitted with a left
femoral neck fracture type Garden 1 after a fall in
October 2002. Initially, she received conservative
treatment for this fracture. In April 2003, she returned
to the hospital with increasing pain in her left leg. Plain
x-rays showed a femoral head necrosis, and the decision
was made to place a total hip prosthesis. During the
reposition maneuver, a mid-shaft femur fracture oc-
curred, which was managed with a dynamic compres-
sion plate with 14 holes. She had persistent wound
leakage after 10 days and elevated C-reactive protein (96
mg/L), so on suspicion of a periprosthetic joint infection,
the patient was taken to the operating room for
extensive debridement and deep cultures. The wound
cultures showed coagulase-negative staphylococci sen-
sitive for vancomycin and rifampicin. She received these
antibiotics intravenously, and after 6 weeks of treat-
ment, she was clinically stable and discharged from the
hospital with a non–weight-bearing regime for 3months
and a full weight-bearing regime after that period.
Six months later, she returned to the hospital with a
plate fracture, probably related to a fall, and a revision
osteosynthesis was planned. During the procedure, 4
tissue cultures were taken from the fracture side, the
plate was revised, and allograft bone was placed. One of
the cultures was positive for C albicans. In consultation
with the microbiologist, this was considered contamina-
tion of the culture and was not targeted with antibiotics.
Another 6 months later, she fractured her proximal
femur and the dynamic compression plate again while
walking with full weight bearing. Infection pseudoar-
throsis was suspected, and it was decided to remove the
implant and obtain 6 cultures. Gentamicin-loaded
cement beads were placed to ﬁll the dead space, and
traction was given to keep soft-tissue length. It was felt
necessary to exactly establish the kind of infection before
a deﬁnitive treatment plan could be made. Of 6 cultures,
4 were positive for C albicans and coagulase-negative
staphylococci. Systemic ﬂuconazole as well as vanco-
mycin was given. It was a difﬁcult nursing situation and
decubitus started to develop. In close collaboration with
a microbiologist, a pharmacist, and local and foreign
experts new management was decided.
A second, more extensive debridement was done, the
acetabular component was removed, and a cement
spacer was created by using a long gamma nail (Stryker,
Mahwah, NJ) coated with 4 batches of Palacos RG bone
cement (Heraeus, Wehrheim, Germany) (Fig. 1). Weincorporated powdered antibiotic (500 mg gentamicin
and 1000 mg vancomycin) and powdered antifungal
(1000 mg voriconazole and 250 mg amphotericin B)
into 40 g of polymethyl methacrylate (PMMA) bone
cement. Consequently, the total antimicrobial content
was approximately 7% wt/wt.
Once the cement became sufﬁciently doughy, it was
hand-molded around the nail, and a cement head was
clayed manually. The spacer was stable, and it allowed a
good range of motion. Rotational stability was provided
by locking the nail with the distal screw. Serum and
drain ﬂuid levels for voriconazole and amphotericin B
were determined 24, 48, and 72 hours after surgery (see
Table). The direct postoperative course was unremark-
able, with nice wound healing. Our patient's previous
left leg pain decreased dramatically. Five weeks after the
initial spacer placement, our patient was given oral
suppressive treatment with ﬂuconazole and was dis-
charged, weight bearing as tolerated, to a nursing home.
At the 3 months of follow-up, the patient remained
clinically stable, and laboratory ﬁndings were normal.
She was able to transfer short distances without pain and
practice her muscles. The spacer was removed, and a
tumor prosthesis was placed (GMRS; Stryker), and the
cup (SHP; Biomet Orthopedics, Warsaw, IN) was ﬁxed
with a full dose of Simplex P bone cement (Stryker),
hand-mixed with voriconazole (Fig. 1). Tissue cultures
were negative, and there were no further postoperative
complications. Six years after placement of the tumor
prosthesis, our patient is still satisﬁed and mobilizing
fully weight bearing with 1 cane, blood parameters for
infection remain normal, and radiographs show no
evidence of loosening or infection.
Discussion
Standard spacers and commercial devices such as the
PROSThesis of Antibiotic Loaded Acrylic Cement
(PROSTALAC; DePuy, Leeds, United Kingdom) have
different sizes of the femoral component to fulﬁll patient
needs [9]. For cases with severe femoral bone loss, there
are not many options available though. Rodriguez and
Ziran [10] reported the case of a handmade antibiotic-
coated gamma nail as a temporary spacer during staged
reconstruction of an infected proximal femur nonunion.
They recognized using the gamma nail as a cost-effective
alternative for commercially available, prefabricated
spacers. Besides ﬁlling the dead space and preventing
limb shortening, our spacer should eradicate the fungal
infection. There is no consensus regarding the type and
dose of antifungal agents that can be used to mix with
bone cement to treat periprosthetic joint infection.
Pharmacokinetics, safety, published reports, drug in-
teractions, and isolate susceptibility must be considered
when selecting a therapy [11]. Furthermore, the drugs
should be heat-stable and easy to dissolve in water.
Theoretically, amphotericin B seems to be an ideal agent
Fig. 1. X-ray of the hip. Left: AP image of the custom-made spacer impregnated with voriconazole, amphotericin B, vancomycin,
and gentamicin; Right: anteroposterior image of the deﬁnite GMRS prosthesis.
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stability, broad antimicrobial spectrum, and availability
in powder form [2,12]. In vitro research, however,
showed very low elution of amphotericin B from
Simplex bone cement [8]. Marra et al [4] performed
an in vivo study of the elution of amphotericin B from
Palacos bone cement (Heraeus, Werheim, Germany).
They detected a maximumwound ﬂuid concentration of
3.2 mg/L and an undetectable serum concentration 50
hours postimplantation. The concentrations of antifun-
gal agents mixed with the bone cement powder in both
studies were subsequently lower compared with our
impregnated cement. In a large, multicenter study,
Kullberg et al [13] state that voriconazole is as effective
as the commonly used strategy of amphotericin B in
nonneutropenic patients for the treatment of candide-
mia, including C albicans. In a recent report, Rouse et al
[14] added voriconazole to Simplex cement and gained a
concentration above the minimal inhibitory concentra-
tions (MIC) 90 value for C albicans in the continuous
ﬂow chamber experiments. Their experiment, however,
was not performed in a clinical situation.
In our case, the elution of both voriconazole and
amphotericin B was good; this report documents
clinically detectable elution of these agents from bone
cement for at least 72 hours. Moreover, all the elution
levels of the antifungals were well above the MIC levelsTable. Elution Levels of Amphotericin B and Voriconazole 24, 4
Antifungals
Drain (μg/mL) Seru
24 h 48 h 72 h 24 h
Amphotericin B 0.6 1.2 1.1 0.1
Voriconazole 5.0 5.0 5.0 0.389
* Minimal inhibitory concentrations determined for C albicans in
Standards M27-A2.determined for C albicans in accordance with the
National Committee for Clinical Laboratory Standards
M27-A2 (see Table). The higher the antimicrobial
content in bone cement, the more porous the cement
matrix will become. Because porosity determines
antimicrobial release [15], our detectable elution can
be explained with the high content of antimicrobials.
This content was chosen based on expert opinion and
scarce literature, susceptibility of the Candida isolate,
elution proﬁles of Palacos cement for other antimicro-
bials, and safety levels of the different drugs we used.
However, with the increase in the amount of antimi-
crobials incorporated, the hardening time of the cement
becomes considerably reduced [16], and it requires some
skills to prepare spacers within the time available.
Furthermore, the acrylic cement becomes brittle when
the content of antimicrobials becomes too high, and
consequently, the spacer will lack sufﬁcient strength for
our load-bearing application.
We believe that the combination of systemic and local
antifungals mixed in bone cement is a good solution to
treat severe fungal joint infections, as is local application
of vancomycin to treat and/or prevent bacterial in-
fections [3]. As a result of our experience with this
patient, we suggest close cooperation between various
disciplines to ensure proper management and a success-
ful outcome after a rare type of periprosthetic infection.8, and 72 Hours After Spacer Implantation
m (μg/mL) MIC (μg/mL)
48 h 72 h Range MIC 50 MIC 90
0.1 0.1 0.06-1.0 0.25 1.0
0.442 0.571 0.015-0.03 0.01 0.03
accordance with the National Committee for Clinical Laboratory
374.e8 The Journal of Arthroplasty Vol. 28 No. 2 February 2013In addition, our patient had no risk factors for a fungal
infection. Candida infection should be considered in all
cases, even in immunocompetent hosts, and not be
regarded as “contamination”.Acknowledgments
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